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Foreword
A confirmed political will to address the drugs problem in Europe lies not only in the develop-ment of appropriate policies, but in the amount 
of public funds assigned to implement cost effective 
policies. Currently, however, analysing what these 
funds are is still difficult. Information and data are 
still sparse and national estimates tend to neither use 
comparable definitions nor agreed methodologies. 
Supply reduction is an approach used for addressing 
the illicit drug phenomena. It comprises the whole 
system of laws, regulatory measures, courses of action 
and funding priorities intended to reduce the avail-
ability of illegal drugs. The EU Drugs Strategy (2013-
2020) sets the dissemination of the evaluation of 
interventions results as a priority. Providing sound 
methods to estimate drug-related public expenditure 
is an important step in this direction. Such estimates 
aim to calculate the amount of resources spent on 
implementing targeted interventions and may reveal 
the extent to which policy intentions are reflected in 
relevant budgets.
This publication is a first step towards a systematic 
analysis. It examines a set of recent and representative 
attempts to estimate public expenditure on supply 
reduction policies. Consequently, it proposes a com-
mon set of definitions aiming to establish a common 
basis for understanding such complex subject matter 
and to facilitate comparability in three main dimen-
sions: time, policy and countries. Although the study 
is mainly focused in supply reduction expenditures, 
it reports data on the balance between spending on 
demand and on supply reduction, when estimates 
are available for European countries. To facilitate and 
promote future empirical expenditure studies, relevant 
data sources and methodologies applied in empirical 
estimations are listed and discussed. 
This publication brings together the findings of wider 
study conducted by the Pompidou Group in cooper-
ation with the EMCDDA seeking to identify the unin-
tended effects and associated costs of drug control 
policies. The aim of this publication is threefold. First, 
increase international awareness about the impor-
tance of estimating public expenditure on supply 
reduction initiatives. Second, stress the importance 
of harmonizing definitions and increasing availability, 
comparability and reliability of data as well as methods 
for sound estimates. Third, contribute to developing 
sound estimation practices to obtain accurate, com-
plete and reliable drug policy evaluations. 
Promoting international cooperation and develop-
ing of effective working partnerships between drug 
international organizations, policy makers, specialists 
in accountancy, law enforcement agents and those 
in charge of economic modelling is the way forward. 
While recognising the limitations imposed by currently 
available data sets, this publication sheds light on 
current practice and, in doing so, suggests areas of 
focus for future desired methodological development. 
In this way it hopes that the estimation of drug-related 
public expenditure and policy evaluation will move 
forward, in Europe. For continuous improvements to 
take place, however, it is essential that partnerships are 
extended and maintained with the goal of developing 
good practices, standards and guidelines in this field.
Jan Malinowski 
Executive Secretary of the Pompidou Group
Alexis Goosdeel 
Director of the EMCDDA
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Executive summary
S upply reduction has been normally used for addressing the illicit drug phenomena in Europe. It uses the whole system of laws, regulatory mea-
sures, courses of action and funding priorities used 
by governments and their representatives. 
Evaluating drug policy is an integral part of a cost-ef-
ficient approach to tackle illicit drugs. Assessing and 
estimating drug-related public expenditure is a first 
step in evaluations exercises. Estimates aim to cal-
culate the amount of resources spent, or needed, to 
implement these targeted interventions. Therefore, 
estimates may reveal to what extent policy intentions 
are reflected in relevant budgets, if considered that 
the size of the phenomena and resources available 
condition choices.
Until now, estimates for the funds spent by govern-
ments in this field are sparse. They have been mostly 
produced at national level and applied different defi-
nitions, with no commonly agreed methodologies or 
comparable datasets. Uncertainty about the most 
appropriate economic models to use also exists. These 
factors have constituted effective barriers to rapid 
developments of policy evaluation and cost-effective 
analysis in the field.
This report takes a first step towards a systematic 
analysis, by examining a set of representative attempts 
to estimate public expenditure on supply reduction 
interventions. It proposes a common set of defini-
tions, aiming to establish a common basis for under-
standing this topic and facilitating comparability in 
three main dimensions: time, policy and countries. 
Although it is mainly confined to supply reduction 
expenditures, in order to set the context, it describes 
the proportion that total drug-related expenditure 
represents of national public spending and; presents 
the balance between demand and supply reduction 
spending for a number of European countries. With 
the aim of facilitating and promoting future empirical 
expenditure studies and of setting the ground for the 
development of good practices, relevant data sources 
and methodologies applied are listed and discussed 
and examples of sectorial models of public spending 
are selectively provided. Finally, some conclusions and 
recommendations are offered. 
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Introduction
T he aim of this publication is threefold. Firstly, to increase international awareness concerning the importance of estimating public expenditure on 
supply reduction initiatives. Secondly, to raise public 
awareness of the need to agree upon harmonising 
definitions and increasing the availability, compa-
rability and reliability of data, as well as methods for 
producing sound estimates. And thirdly, to contribute 
to developing national and international estimation 
practices with a view to obtaining accurate, complete, 
reliable and comparable drug policy evaluations.
The target audience includes officials involved in the 
evaluation of drug policy; entities wishing to evaluate 
drug policy priorities, develop drug policy strategies 
and action plans and analyse their economic, social 
and political consequences; accounting authorities; 
entities seeking funds to finance their service provi-
sion; and researchers.
Most European countries have a national drug policy 
presented in a drug strategy document (EMCDDA, 
2015). National drug strategies tend to reflect a bal-
anced approach between drug demand and drug 
supply reduction (EMCDDA, 2016). An optimal balance, 
however, may not imply that the two approaches 
receive an equal share of resources and attention. 
Instead, it will depend on country specific priorities 
and aims for the different drug policy sectors, as well 
as on the relative price of implementing each activity 
in a cost-effective manner. 
Supply reduction is often the main approach used 
for addressing the illicit drug problem. Nonetheless, 
efforts aimed at reducing demand (mainly prevention 
and treatment measures) are also important and 
harm reduction initiatives have gained in significance 
over the years. In addition, the effects of supply and 
demand reduction efforts are often interrelated. For 
instance, successfully reducing drug availability may 
influence the consumption of drugs and also have an 
impact on problem drug use and adverse drug use 
consequences. 
The overarching objective of supply reduction is a 
measurable reduction in the availability and accessibil-
ity to illicit drugs. Supply reduction initiatives comprise 
the whole system of laws, regulatory measures, courses 
of action and funding priorities concerning illicit drugs 
put into effect by a government or its representatives 
(law enforcement officers such as police and customs 
officers, judges, prison guards, etc.). Reduced drug 
availability and accessibility is achieved through a 
disruption of illicit drug trafficking; dismantling of 
the criminal organisations that are involved in drug 
production and trafficking; efficient use of the criminal 
justice system; effective intelligence-led law enforce-
ment and increased intelligence sharing; and a focus 
on large-scale, cross-border and organised drug-re-
lated crime (EMCDDA, 2016). 
As stated in documents such as the 2013-2020 
European Union Drug Strategy (Council of the 
European Union, 2013) and the EU Action Plan on 
Drugs 2013-2016 (Official Journal of the European 
Union, 2013), an evaluation of drug policy is an inte-
gral part of the approach to combating illicit drugs. 
Estimation of drug-related public expenditure can be 
seen as a first step in this direction. Public expenditure 
estimates aim to calculate the amount of resources 
spent, or needed, to implement targeted interventions 
in a particular policy field and may reveal to what 
extent policy intentions are reflected in the relevant 
budgets and are conditioned by the size and charac-
teristics of the drug phenomenon. 
Accurate estimates of public spending on implement-
ing drug policy initiatives will help policymakers to 
plan relevant interventions and make the required 
funds available to the authorities in charge of policy 
implementation. A thorough assessment of drug 
policy expenditures will also contribute to improved 
transparency and accountability of public institutions. 
Estimates may provide information on factors such 
as the relative importance of demand and supply 
expenditures and enable cross-country comparisons 
of the level and composition of spending on the fight 
against illicit drugs (EMCDDA, 2008). Sound planning, 
improved knowledge of the resources allocated to this 
policy field, and cost-effective resource allocation are 
particularly necessary in times of economic downturn 
when fewer resources are available. 
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A subsequent step would be to systematically compare 
public expenditure and other possible costs to the pol-
icy’s measured outputs or results. Depending on how 
the results are defined and measured, a cost-benefit or 
cost-effectiveness analysis can be conducted (see glos-
sary). In this case, resource inputs (the costs of labour, 
capital and/or equipment) are linked to intermediate 
outcomes (e.g. number of drug dealers arrested); final 
outputs (e.g. lives saved, life years gained, number of 
drug users, reduction in drug-related harm, percent-
age reduction in crimes committed); or policy goals. 
Irrespective of the chosen output measures, however, 
public expenditure will be a central cost factor, since 
governments constitute the main provider of drug 
supply reduction services in Europe.
A thorough economic evaluation can provide pol-
icymakers with the information required to make 
well-informed decisions. Although the data and a 
quantification of all the outcomes and cost elements 
required for conducting the most comprehensive 
analyses are currently not available, a somewhat less 
extensive analysis and an improved understanding 
of the individual elements involved are still possible, 
useful and desirable. This report takes the first step 
towards a systematic analysis by examining a num-
ber of representative attempts to estimate public 
expenditure on supply reduction policies. It proposes 
a common set of definitions to be used for public 
expenditure assessment and evaluation. In addition, 
it aims to establish a common basis for understanding 
this complex subject and to facilitate comparabil-
ity in three main areas: time, policy and countries 
concerned. Although, the report mainly focuses on 
supply reduction expenditures, in order to contex-
tualise them, it describes the proportion that total 
drug-related expenditure represents of gross domestic 
product. It also shows how spending is balanced 
between demand and supply reduction initiatives 
in a number of European countries. To facilitate and 
promote future empirical expenditure studies, the 
relevant data sources and methodologies applied in 
making empirical estimates are listed and discussed. 
Examples of sectorial models of public spending and 
examples of national supply reduction expenditure 
studies are also provided. Finally, some conclusions 
and recommendations are offered. 
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Defining concepts
Public expenditure
The term «public expenditure» refers to the value of 
goods and services purchased by  general govern-
ments (at central, regional and local level) in order to 
perform its functions. For instance, it refers to resources 
spent on healthcare, justice, public order and safety, 
education, social protection and so on (Eurostat, 2011), 
and its quantification is a costing exercise undertaken 
from the government’s perspective (EMCDDA, 2008). 
The role of private expenditure in drug policy varies 
across countries, timescales and policy areas. In many 
countries, drug treatment is partly financed by the 
private sector (insurance companies, drug users or 
their employers, relatives, etc.). In other drug policy 
areas, such as supply reduction, private funding usu-
ally constitutes a negligible share of total spending 
(European Commission, 2012). 
Drug-related public expenditure
Drug-related public expenditure is the sum spent by 
governments on goods and services with the aim 
of tackling the illegal drug phenomenon. Although 
drug policy expenditure estimates are deemed useful, 
most countries do not produce separate drug-related 
budgets as part of their ordinary budgeting exercise. 
Relevant analyses and estimations can be complicated 
since several inter-ministerial and cross-governmental 
sectors are involved in drug control programmes, 
including justice, policing and border control, prisons, 
social protection, education and health. Disentangling 
drug policy expenditure across government depart-
ments and inter-sectorial policies remains a significant 
challenge. Changes in legislation and the structure of 
public administration can further hamper compara-
bility over time.
An additional challenge lies in the fact that drug-re-
lated programmes and activities can be found at many 
different levels of public administration. For instance, 
the funding for imprisoning drug-law offenders is usu-
ally provided by central government, while prevention 
of street dealing or social reintegration programmes 
for former drug dealers are frequently financed by 
local authorities. This makes it necessary to compile 
data at different administrative levels, which can be 
a demanding task. 
In addition, often only a small fraction of drug- related 
public expenditure can be traced back directly to 
government documents or single budget lines; 
these are labelled expenditure. The required data 
are instead embedded in budgets for larger sectors 
or programmes (unlabelled expenditure), which 
means that modelling and calculations are needed. 
For instance, it is common that prisons do not have a 
separate budget for drug-law offenders, because they 
usually have one single budget for their entire activity. 
Therefore, the values of this embedded expenditure 
can only be estimated through modelling approaches 
(EMCDDA, 2014). This requires skills, modelling tools 
and techniques. 
Despite the various factors which may challenge the 
robustness of estimation results (limited data availabil-
ity, layering of assumptions, changes in definitions or 
regulations over time, etc.), the application of existing 
models can provide useful insights, as various coun-
tries’ experience shows (see the examples below). 
Public expenditure on supply 
reduction initiatives
In this report, public expenditure on drug supply 
reduction comprises the funds spent by general gov-
ernment with the broad purpose of reducing the 
availability with the support of the police, law courts 
and prison services geared towards combating the 
illegal drug phenomenon, as defined by Eurostat 
(2011). In general, police services comprise, among 
others, the regular and auxiliary policing of ports 
and borders, coast guards and customs, as well as 
road traffic regulations and supervision. The services 
provided by law courts comprise the operation or 
support of civil and criminal law courts and judicial 
systems, the prosecution service, fine enforcement 
and probation systems. Prison services comprise the 
activities of prison administration and the operation or 
support of prisons and other places for the detention 
or rehabilitation of offenders, such as prison farms, 
workhouses, reformatories, borstals, forensic wards, 
etc. (Eurostat, 2011). 
In the case of public expenditure on drug supply 
reduction initiatives, the vast majority of resources 
will be spent on enforcement targeting producers and 
dealers, but may also include legal action targeting 
users for drug possession when required by national 
judicial systems.
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Empirical estimates of demand 
and supply policy expenditure
O ver the last decade at least 16 European coun-tries have provided comprehensive estimates of drug-related public expenditure (EMCDDA, 
2014b). Country estimates suggest that drug-related 
expenditure ranged from 0.01% to 0.5% of gross 
domestic product (GDP). Since the studies may not 
have applied the same expenditure classifications 
or the same estimation methods, caution is required 
when making cross-country comparisons (EMCDDA, 
2014b). 
Interestingly, however, the information available sug-
gests that supply reduction activities accounted for 
the largest share of drug-related public expenditure 
in most countries. Of the 16 countries which pro-
duced complete estimates in the last decade, only 
four countries spent less than 50% of their total drug 
budget on supply reduction, while five countries spent 
70% or more. The other countries spent between 
50% and 70% of their drug-related expenditure on 
supply reduction. 
Figure 1 Breakdown of drug-related expenditure between demand and supply reduction. 
Source: EMCDDA, 2014b
Analysis has also shown that funds allocated to 
drug-related initiatives account for only a small pro-
portion of the overall public expenditure on the public 
order and safety sector. For instance, in 2008 (the only 
year this exercise was systematically conducted in 
European Union countries), supply reduction expendi-
ture represented between 2% and 12% of total public 
expenditure in this sector. This proportion compares 
to the proportion of drug-related spending on the 
health and social protection sectors. The proportion 
of drug-related expenditure on these items accounted 
for less than 1% of total public spending on health 
and social protection during that period. Since most 
public spending on demand reduction initiatives is 
classified under health and social protection, this 
may further suggest that European countries give 
higher political priority to supply reduction initiatives, 
as part of public order and safety activities, than to 
demand reduction initiatives as part of overall public 
health activities (EMCDDA, 2008). Annually, EMCDDA 
reports the most recent estimates available for national 
drug-related public expenditure in percentage of 
the gross domestic product (GDP), in the European 
Union countries, Norway and Turkey. When available, 
EMCDDA reports also the proportion of funds spent 
on supply reduction initiatives (http://www.emcdda.
europa.eu/countries). 
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Steps in cost estimation 
and analysis
C larifying definitions, improving estimation methods, agreeing on best practices and find-ing reliable, standardised data will enhance the 
utility of public expenditure estimates, as analysis 
over time and across policy areas and countries can 
be improved(Single, 2009). Better quality data and 
further methodological developments are needed. To 
this end, we list below some recommended, general 
methodological steps in cost estimation and analysis. 
Defining the scope and objects
Globally speaking, a first step for a viable estimate is 
defining the scope and type of public expenditure 
considered. In addition, clear indications of the geo-
graphical area and which function of public service 
provision the estimates cover are needed. 
Making an inventory 
of service providers
Secondly, it is necessary to identify the public entity 
or institutions responsible for the provision of drug-
related services – in the case of this report supply 
reduction measures and interventions. The govern-
ment authorities and public institutions and services 
responsible for the implementation of the drug policy 
initiatives, on the different competency levels, have 
to be made an inventory. 
Mapping financing entities
The third step is then to identify who finances these 
service providers. The starting point for a public expen-
diture analysis is accordingly the different public 
authorities which fund the respective aspects of the 
drug policy. Irrespective of the governmental struc-
ture, expenditure by all relevant national, regional 
or local government institutions, directly or indi-
rectly associated with drug policy, should always be 
included.
Matching stakeholders responsible for providing drug 
policy services with their financing entities can be chal-
lenging, as the entities in charge of providing public 
services are not always obvious and easy to identify. 
For instance, when drug treatment services are pro-
vided within prisons, the entity in charge has public 
order and safety as its first function but health as its 
“real” goal. Therefore, analysts must consider whether 
to include the costs of these activities as supply reduc-
tion or demand reduction initiatives. Eurostat, along 
with most international organisations concerned with 
policy evaluation, includes the provision of services 
in the main function that the funds are used for, even 
where the provider is less obvious. In this case, public 
expenditure on drug treatment provided in prisons 
should be excluded from expenditure estimates for 
supply reduction services and accounted for as drug-
related health expenditure. Sometimes, provision will 
be the responsibility of private entities while financing 
is a government responsibility. 
It should be noted, however, that the same service 
may have multiple policy purposes and double count-
ing should be avoided. For instance, in the case of 
social reintegration programmes in deprived neigh-
bourhoods, financing may serve both the purpose 
of preventing drug crime (and should be added to 
supply reduction expenditure) and the purpose of 
preventing drug use (and should also be accounted 
for as health spending in demand reduction expendi-
ture). For public accounting purposes the same funds 
should not be counted twice. Therefore, researchers 
will have to include this spending only once, choosing 
to record it under either preventive health or crime 
prevention. Sometimes, making a decision is difficult 
and the best way to deal with such situations is to 
guarantee that researchers document the different 
choices and assumptions they make.
Data collection
The fourth step is to determine a strategy for collecting 
the required data on public expenditure. In order to 
obtain the relevant information, analysts will have to 
examine policy documents and accounting data. It is 
also recommended that interviews be conducted with 
the major stakeholders in the field, as a way to obtain 
better information about where financial data might 
be available, and to search for international data sets. 
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Classifying and identifying data 
on drug-related spending
It is essential to classify public expenditure according 
to the purpose for which the expenditure is intended 
(Reuter et al., 2004, and Eurostat, 2011), so the next 
step to consider is how to group drug-related spending 
according to these sub-purposes. Taking into account 
the fact that drug-related expenditure on supply reduc-
tion initiatives comprises funds spent with the aim of 
combating the illegal drug phenomenon through the 
police, law courts and prison service, the classification 
commonly used in international comparisons is the 
Classification of the Functions of Government.1
► The Classification of the Functions of
Government (COFOG) provides a useful frame-
work for classifying public spending according 
to its purpose. Under COFOG, most drug control 
policy expenditure is included in the “public
order and safety” class of expenditure. The most 
directly relevant subclasses are “police services”, 
“law courts”, “prisons” and “R&D public order and 
safety” (Eurostat, 2011).
► Reuter (2006) relates public expenditure to the 
supply and demand sides of the market. He
counts public spending on supply reduction
under “enforcement programmes” and con-
siders that these are “programmes aimed at
traffickers and producers to shift up the supply
curve for drugs; other things being equal, they
should raise the price of drugs and lower quantity. 
Programmes aimed at users and retailers raise
the transaction costs of buying drugs”. In other
words, enforcement programmes will make
drug producing, trafficking or dealing more
expensive, because they either bring about an 
increase in the unitary costs of production or
introduce greater risk into the business (Costa
Storti and De Grauwe, 2009).
These two classification systems are substantially 
different. COFOG has been co-designed by the statis-
tical office of the European Union and the European 
Commission, with well-defined concepts and data 
collection methodologies. Annual mandatory data 
collection has been implemented in every European 
Union member state since early 2000. The system 
covers all functions provided and financed by govern-
ments. Drug-related activities are among the overall 
tasks provided and financed by the public sector, 
but there are no specific methods specified or data 
collected on drug-related expenditure. Drug-related 
expenditure is embedded in broader items, such as 
public expenditure on public order and safety, security, 
health, education or social protection. Conversely, 
the Reuter’s classification was designed to organize 
1.  National estimates sometimes use alternative definitions. 
See (Lievens et al., 2016) or (Kopp, 2006) for further details.
public expenditure spent with the main aim of tackling 
the drug phenomenon. However, no systematic data 
collection has taken place. 
The research community has not formally adopted any 
of these classification systems. However, as Eurostat 
publishes data annually in accordance with the COFOG 
classification, their system is frequently used. Eurostat 
publishes data on public spending with the purpose 
of guaranteeing public order and safety, which is split 
into the above-mentioned classes. Researchers still 
have to opt for criteria and models to disentangle 
drug-related spending within these overall expen-
diture classes.
In fact, supply reduction initiatives are often embedded 
in policy projects that have broader objectives and bud-
gets. Therefore, firstly, it is important to look beyond 
expenditure that is exclusively used for drug policy 
and also include spending intended for broader policy 
domains that indirectly, but significantly, contribute to 
drug policy or impact upon it. For instance, investing 
in effective policing in certain problematic neighbour-
hoods, in order to prevent all types of crime, may also 
contribute to preventing drug dealing. Consequently, 
it is relevant to take into account overall budgets for 
initiatives which may have direct synergies with drug 
policy objectives. Secondly, modelling techniques are 
required in order to disentangle drug-related expendi-
tures from overall expenditures. For instance, specific 
estimates and well-defined methodologies are needed 
to disentangle expenditure on drug-related crime from 
overall public spending on law courts (more details on 
methodologies are given below). 
In the event that not all the required data are available 
in international data sets, national databases should 
be mapped. Every country has different structures 
for drug control services, provision and financing. 
National data mapping can be achieved in different 
ways: information from registration systems, annual 
reports, interviews with key experts and/or contacts 
working in this field (De Ruyver et al., 2007). Detailed 
mapping of available data can be demanding and 
makes intensive use of resources. However, it is a 
fundamental step for any estimate of public spending 
on drugs control.
Extracting expenditure data 
from sources: labelled and 
unlabelled expenditure
Some of the funds allocated by governments for 
drug-related expenditure are identified as such in the 
budget (labelled expenditure). Often, however, the 
majority of drug-related expenditure is not identified 
(unlabelled expenditure) and must be estimated using 
modelling approaches. Total drug-related expenditure 
is the sum of labelled and unlabelled drug-related 
expenditures (EMCDDA, 2016).
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Since labelled expenditures are clearly identified in 
budgets, calculation methods are not required. Time 
series data are often available for labelled expenditure. 
The biggest challenge when data on labelled expen-
diture are compiled is to ensure complete mapping 
of all entities in charge of providing these services, as 
they can be spread across different government levels. 
Depending on the national structures, expenditures 
from all relevant national, regional or local government 
institutions that are directly or indirectly associated 
with drug policy should always be included.
For unlabelled expenditure, a modelling procedure 
is necessary to estimate these different expenditures 
and the modelling is based on either a top-down or 
a bottom-up approach. Frequently, these estimates 
require the use of activity data to develop estimates 
(for example, number of offences, offenders, criminal 
cases, prisoners, etc.)
Modelling unlabelled expenditure
The top-down modelling approach is mainly used when 
the data available are embedded in programmes with 
broader goals and the fraction attributable to drugs can 
be identified as the proportion of the overall budget. 
In order to identify this proportion, models lay down 
objective criteria and calculate attributable fractions. 
Unlabelled drug-related expenditure = Overall expenditure × Attributable fraction
There is no general methodology to determine attrib-
utable fractions also known as repartition keys. In 
practice, the appropriate repartition key is determined 
by the object of the estimate, data availability and the 
modelling approaches available. Repartition keys are 
determined in different ways on the basis of informa-
tion from activity data, extracted from registration 
systems, annual reports and/or contacts working in 
this field (De Ruyver et al., 2007). When determining 
attributable fractions, the data used should prefer-
ably be publicly available or, even better, be stored 
within international databases. This can guarantee 
the possibility of producing similar estimates in the 
years that follow and in other countries.
Appendix 3 summarizes the information and data 
available in the most relevant international data-
bases that can be used to estimate unlabelled public 
expenditure on supply reduction. It describes the 
activity data reported, the reporting countries and 
time periods. 
This Appendix reports the data available concern-
ing the annual statistics on national public expen-
diture on police, law courts and prisons reported by 
Eurostat. These data include not only expenditure on 
drug-related initiatives, but the total spent to tackle all 
types of crime. Therefore, to disentangle drug-related 
expenditure and built attributable fractions, activity 
data shall be required. 
For instance, the number of drug-law offenders in 
prison may allow estimating the proportion that con-
victed prisoners for drug-law offences represent from 
total prison population, and therefore to approach the 
proportion that drug-related expenditure on prisons 
represents from total prison spending; or the propor-
tion that drug-related cases handled by the police, 
by prosecutors or by drug-law courts on the total 
number of cases handled by these institutions may 
allow starting approaching their drug-related costs.
To design attributable fractions, models use the sup-
port of data on crime, police, law courts or prisons 
activity. Appendix 3 presents information and data 
by groups of variables. These groups encompass total 
public expenditure, drug-related public expendi-
ture, supply reduction public expenditure; drug law 
offences; crime reported by the police, drug-related 
crime, conviction statistics and prison population. 
Within groups, variables directly relevant are listed. 
For each variable, data available are listed by source, 
country and time period. Finally, this annex reports 
the number of observations available for each vari-
able. The relevant sources include data from the 
Council of Europe, EMCDDA, EUROSTAT, Univeristeé 
de Criminoligie et de Droit Penal de Lausanne and 
the UNODC. 
Despite that data available are still referent to a short 
period of time and that data are still missing in many 
countries/years, gathering available information shall 
allow developing better methods and more accurate 
estimates in the future. 
When international sources are not available, publicly 
available national statistics and data from competent 
public bodies should be used.
Advantages of the top-down approach
 ► Availability of data: the availability of aggre-
gated budgetary data means that top-down 
approaches can be easily applied.
 ► Low cost: the availability of aggregate cost data 
means that the time and costs required to esti-
mate a top-down unit cost can be reduced.
 ► Versatility: the methodology enables an analyst 
to forecast how costs may change as a result 
of a reduction/an increase in service usage 
(for instance, when there are less/more drug- 
related crimes committed in a certain year than 
expected) and how these costs change over 
time.
There are, however, some limitations associated with a 
top-down approach. Firstly, it does not clearly identify 
the different factors that may drive the costs and there-
fore often masks the underlying factors that determine 
why unit costs vary within a single, yet heterogeneous, 
services group. The criteria laid down for estimating 
attributable fractions do not always take into account 
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all of the characteristics that may impact the total costs, 
which means that cost functions are often simplified. 
These estimates are therefore often not very precise. 
Nevertheless, they are frequently used and provide 
valuable proxy indicators for average costs. 
An alternative method of estimating drug-related 
expenditure is to base estimates on the cost of provid-
ing one unit of public service, known as the bottom-
up modelling approach. This modelling approach 
starts by detailing how much it costs to provide one 
unit of service or intervention. For instance, how 
much does it cost to keep one drug-law offender in 
prison? Considering the different costs borne by the 
government for managing a prison facility, such as 
the real costs of state property, prison staff, electric-
ity, water and gas, machinery, etc., it is possible to 
estimate how much each detainee costs per day. This 
sum can then be multiplied by the number of drug-
related detainees, taking into account the different 
costs associated with each type of detainee, based 
on the different lengths of prison sentences, different 
security levels, etc. To obtain the total expenditure on 
drug control policy, all the cost elements should be 
identified and totalised. 
The bottom-up approach is particularly appealing 
when relevant unit costs are readily available. If, on 
the other hand, every type and element of the drug 
policy has to be separately estimated, the approach 
can be demanding and challenging. 
Advantages of using a bottom-up approach
 ► Transparency: detailed cost data allow potential 
errors to be investigated and their impact tested 
– this facilitates a quality assurance process.
 ► Simplicity: the calculation required to estimate 
unit costs is easy to understand and direct, 
providing a simple way to quantify the admin-
istrative and overhead costs associated with a 
range of public services.
 ► Detail: detailed cost data can highlight vari-
ations, enable analysts to explore the factors 
underlying variations and determine whether, 
for example, some service users account for a 
disproportionate share of the costs.
 ► Versatility: the methodology enables an analyst 
to forecast how costs may change as a result of 
a reduction in service usage or demand.
However, the main disadvantage associated with the 
bottom-up approach is that it requires detailed infor-
mation concerning both the type of costs associated 
with the provision of each service (full knowledge of 
the production function of each public service) and 
the unit cost of each of the production factors. 
A combination of the two approaches may be pre-
ferred. The advantage of this dual method is that 
it makes cross-verification possible; the data gath-
ered on the basis of the top-down approach can be 
double-checked and supplemented with the data 
retrieved from project actors in the field.
Reporting the value of estimates
The basic format used to report the value of estimates 
is monetary value in nominal terms. However, to per-
mit comparability over time, if reported in monetary 
units estimates should be adjusted for inflation. 
In addition, some authors report the value as a per-
centage of GDP. This way of presenting the results 
considers the economic dimension of a country. It is 
likely that drug-related spending is higher in a country 
with 85 million inhabitants than in a country with 
10 million inhabitants. The same holds for a higher 
income country (EMCDDA, 2008). For these reasons, 
reporting the value of estimates as a percentage 
of GDP is a valid choice, since it takes account of 
both the inflation problem and the size and level of 
a country’s income.
Another frequently used approach is reporting the 
value of spending per number of problem drug users. 
In this case, authors take into account the dimension 
of the drug problem. Reporting all these complemen-
tary measurements of drug-related public spending 
facilitates the validation of the data through cross-ver-
ification and increases the economic significance and 
utility of the estimates.
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Examples of sectorial models 
I n addition to collecting labelled public expenditure data, several examples exist of models applied to identify unlabelled expenditure on drug control in 
the national contexts. Different authors have applied 
different definitions, data sets and models to estimate 
items of drug-related expenditure. In this section, 
examples of the definitions, data and models are 
provided. The section aims to present the models 
utilised to estimate unlabelled drug-related spending 
on various types of supply control initiatives. 
Police
Public spending on drug-related police services is 
probably best identified using a top-down approach.2 
In order to disentangle this expenditure from total 
public expenditure on public order and safety, as 
published by Eurostat, attributable fractions has been 
calculated with the help of activity data. Authors 
have used auxiliary data to create these fractions, for 
instance data on drug-related offences in proportion 
to the total number of offences. The following are 
concrete examples of variables available in national 
and international data sets, which have all been used 
separately to estimate attributable fractions:
(1) The number of drug-related crimes per 100 000 
population.
(2) The number of drug-related cases reported 
by the police out of the total number of police 
cases.
(3) The time the police forces spend on combating 
the drug phenomenon in proportion to their 
total working time.
To estimate the share of costs attributable to spend-
ing on police action against illicit drugs, the ratio is 
multiplied by the total expenditure of the law enforce-
ment agencies and reduced by any available data on 
labelled expenditure for drug control. 
A concrete example is provided by the estimates for 
Italy. Genetti (2014) estimated drug-related public 
expenditure for police forces based on the amount 
of time that staff spent on drug control in 2011: pos-
session of illicit drugs for personal use; production, 
2.  Although it is also possible to use a bottom-up approach, 
since police activity is normally financed by the central 
government budget, a pragmatic approach frequently used 
is to prepare estimates based on these aggregated budgets. 
In this case, estimates for public spending are relatively 
complete, considering all relevant costs. Additionally, this 
method facilitates the international comparability of results, 
since comparable data are available for most European 
countries.
trafficking and dealing in illicit drugs; and driving 
under the influence of drugs and alcohol. The pro-
portion that this time represented of the total work-
ing time for the police forces was then used as an 
«attributable fraction» for disentangling the amount of 
money that was spent on drug-related police activities 
from the total spending on police activity. Within the 
funds allocated for supply reduction, 14% was spent 
on drug-police activity, while law courts and prisons 
absorbed the remaining 21% and 65% respectively.
Moolenaar (2009) developed a model and provided an 
example of how to estimate public spending on supply 
reduction initiatives in the Netherlands. The author 
applied a top-down model based on the average cost 
of police time spent on this work. Moolenaar calcu-
lated the average duration of each type of criminal 
investigation firstly by type of criminal activity (assum-
ing that different criminal activities have different 
investigation costs – based on an assessment of the 
severity of the crime) and secondly by the number of 
cases registered for each criminal activity.
Customs
With regard to customs services, the share of customs 
officers who deal with drug control activities and/or 
the proportion of their working time compared to 
the total number of custom officers has been used 
as an attributable fraction. As input data, the number 
of customs officers who are involved in drug control 
activities forms the basis for the calculation. These 
estimates are then applied to the total expenses of the 
customs administration (minus any labelled expen-
diture specifically targeted towards this activity). It 
should, however, be noted that most customs officers 
do not exclusively devote their working time to drug 
control activities, so, ideally, the percentage, or the 
average, of working time devoted to drug control 
should be estimated.
Kopp and Fenoglio (2002) estimated the drug-related 
expenditure of customs services based on the propor-
tion of customs officers allocated to combating illicit 
drug trafficking within the total number of customs 
officers. This proportion constituted the attributable 
fraction applied to the total customs budget. The 
authors concluded that, in 2000, drug-related spend-
ing on customs services represented approximately 
10% of total drug-related spending in France. As these 
authors pointed out, omitting costs such as those of 
detection equipment or detection dogs may consti-
tute a relevant limitation, since the costs of detection 
equipment may have a strong impact on relatively 
small budgets such as that for customs.
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Lievens et al. (2016) estimated drug-related expendi-
ture by customs based on the proportion that drug-
law violations represented in the total number of 
violations registered by the ordinary customs services, 
investigation services and motorised brigades. They 
used a top-down approach based on the number of 
drug-law offences in proportion to the total number 
of offences. In 2012, customs spending represented 
3.6% of the total drug-related public spending on 
supply reduction in Belgium.
Court systems
Spending on drug-related court services has been 
extracted from total national expenditure on law 
courts based on the following activity data: 
(1) The proportion of drug-related offences with
regard to the total number of offences.
(2) The proportion of drug-related convictions with 
regard to the total number of convictions;
(3) The proportion of people imprisoned for
drug-related offences with regard to the total
number of prisoners.
Kopp and Fenoglio (2002) estimated the expenditure 
that drug-related crime represented in the French 
judicial system. They adopted a bottom-up approach, 
taking estimates of the time spent by the various 
types of French judges and other types of adminis-
trative staff on drug-law cases and then multiplying 
these estimates by their average salaries. Based on 
this method, the authors concluded that law courts 
represented about 24.4% of total drug-related public 
expenditure in France in 2000.
In Croatia, drug-related spending on the courts 
covered drug-related cases prosecuted by both the 
State and the courts (Budak et al., 2013). A top-down 
approach was used based on estimates of the num-
ber of drug-related crimes as a proportion of the 
total number of crimes registered by the police. The 
researchers recognised that these estimates were 
crude, but they could not obtain a better proxy for 
this particular component of the estimates. 
In Sweden, expenditure on drug-related prosecutions 
and court cases (district court, court of appeal and 
supreme court) was estimated based on a bottom-up 
approach, which combined the number of cases and 
the average cost per case (Ramstedt, 2006). The data 
were obtained from a judicial system official. It should 
be noted that the average case cost was not recorded 
by type of crime, instead the average for all types 
of crime was used as an indicator for drug crimes. 
Moreover, for the court of appeal and supreme court, 
only the total number of criminal cases was available 
and the fraction of drug cases was estimated based 
on the situation in the district courts (9%). Regarding 
the range of the estimates it should be noted that 
the author included, as an upper limit for estimates, 
a specific percentage (30%) of the costs of tackling 
other crimes, as they may have been committed under 
the influence of drugs. 
Prisons
Unlabelled costs of drug-law offenders in the prison 
system can be estimated using the number of con-
victed prisoners for drug-related offences expressed 
as a proportion of the number of overall convictions. 
For example, to estimate expenditure related to drug-
law offences in prisons, two elements have been taken 
into account: overall prison expenditure for a given 
fiscal year and the attributable fraction of prisoners 
convicted of drug-law offences. 
EMCDDA (2014) provides an example of how public 
expenditure on drug-law offenders in prisons can be 
estimated. Based on data for public expenditure on 
prisons provided by Eurostat and data on the number 
of offenders provided by the Council of Europe, the 
proportion of prisoners sentenced for a drug-law 
offence as their main offence was applied to the total 
public expenditure on prisons. A range of estimates 
was calculated, with low estimates taking into con-
sideration only prisoners sentenced for a drug-law 
offence and high estimates also including pre-trial 
prisoners. Between 2000 and 2010, this expenditure 
was estimated to range, on average, between 0.03% to 
0.05% of GDP in 22 European countries. On applying 
these percentages to the entire EU for the year 2010, 
the estimated expenditure was within the range of 
3.7 billion euros to 5.9 billion euros.
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Examples of national studies
S everal models and data sources have been applied in different national contexts to identify labelled and unlabelled expenditure allocated to 
drug control initiatives. Due to national specificities, 
neither their external validity nor the comparability 
of the methods used have been tested. The extent 
and specificity of labelled drug-related expenditure 
vary substantially across countries, as do the data and 
methods applied for estimating unlabelled expen-
diture. The national estimates presented below are 
therefore not directly comparable. They nonetheless 
provide examples of useful models and estimates and 
illustrate some of the approaches applied. 
Croatia
Budak et al. (2013) aimed to identify the central gov-
ernment’s total drug-related public expenditure and 
to develop a method of estimating and allocating 
unlabelled expenditure by type of drug policy pro-
gramme (prevention, treatment, social reintegration, 
harm reduction and law enforcement). For labelled 
expenditure, governmental institutions were asked 
to classify budget expenditure by public function 
and by type of programme. Unlabelled expenditures 
were identified indirectly with a system of reparti-
tion keys, which were applied to the total state unit 
budget (minus labelled costs). The repartition keys 
were estimated using supply reduction activity data. 
Unlabelled public expenditures were estimated on 
the assumption that they make up the part of public 
expenditure remaining after labelled public expendi-
tures for combating drug abuse have been deducted 
from the total expenditure of a public body. 
For the period 2009-2012 the study suggested that 
public expenditure on law enforcement constituted 
about 73% of total drug-related public expenditure by 
central government, whereas prevention, treatment, 
social reintegration and harm reduction represented 
12%, 13%, 0.3% and 2%, respectively. When comparing 
unlabelled expenditure for the different programmes 
in a single year (2011), unlabelled expenditure on law 
enforcement represented 82% of total unlabelled 
drug-related expenditure. On the other hand, law 
enforcement accounted for 4% of the total labelled 
expenditure. Overall, the estimates indicated that 
drug-related expenditure stood at 0.2 % of the GDP.
Belgium
The study Drugs in Figures III measured how much 
the Belgian Government spent on drug policy in 
2008 (Vander Laenen, De Ruyver, Caulkins & Lievens, 
2012). It further developed upon two earlier stud-
ies (De Ruyver et al. 2004, 2007) by carrying out a 
new and more refined estimation of public expendi-
ture to combat illegal drugs. The study combined a 
top-down and a bottom-up approach for estimating 
public expenditure. The vast majority (98.45%) of 
the expenditures were identified as a result of the 
top-down approach. Public expenditures identified 
through the bottom-up approach (1.55%) concerned 
organisations that depended on the government for 
most of their funding.
The total drug-related expenditure was broken down 
by programme: law enforcement, treatment, pre-
vention, harm reduction and other. For 2008, public 
expenditure on law enforcement constituted 45% of 
the total expenditure. This was slightly less than the 
spending on treatment (49%) and substantially more 
than that on prevention (4%), harm reduction (0.8%) 
and other (1.2%). When estimated in the same way in 
2004 and 2008, public expenditure on law enforce-
ment showed a substantial increase, both nominally 
(from 186 038 337 euros to 243 000 490 euros) and 
in relation to the other programmes (it increased by 
6 percentage points).
Italy
For the purpose of estimating drug-related public 
expenditure in Italy (Reitox Italian Focal Point, 2014), a 
model was developed to analyse the flow of cost infor-
mation from various sources. The model consisted of 
four components: private or indirect costs (individual 
costs and costs due to loss of productive capacity) and 
public expenditure or direct costs (law enforcement 
costs, social and health costs). To determine the costs 
of law enforcement, different sources of information 
were used: data concerning traffic control and traffic 
accidents; police data on people caught with drugs 
for personal use; data on the number of convictions 
for drug trafficking; and data on crimes related to 
drug trafficking.
For 2011, the cost of drug-related law enforcement 
was estimated at 1 600 435 296.60 euros, or roughly 
40 euros per inhabitant aged 15-64 years. The largest 
cost component was prisons and alternative measures 
(65%), whereas trials and legal expenses, law enforce-
ment activities and administration represented 21.3%, 
13% and 0.7%, respectively.
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France
In a French study the method relied on analysing 
activity records, wherever available in the agencies 
concerned (Kopp, 2015). The total expenditure for drug-
related activities was then aggregated. The top-down 
approach applied in this case provided an indication of 
the proportion of expenditure for drug control related 
activities compared to the overall expenditure of all 
the institutions and agencies concerned. To obtain an 
estimate, a fraction was applied to the total staff and 
routine operating costs of the agency concerned. In the 
year 2010, for example, 10% of police activities were 
attributable to drug control activities, which involved 
60 police units. In this example, police expenditures 
attributable to drug-related activities were calculated 
by multi plying the total expenditure of the police 
services by this fraction of 10%. 
A bottom-up approach was also adopted, based on the 
working time of staff performing support functions in 
connection with drug-related activities or the equip-
ment used, as recorded by the agencies concerned. 
For example, the time spent giving prevention talks 
in schools and the time spent by the police forces on 
alcohol tests were included in the calculations.
Luxembourg
Since 1999, the social costs of drugs have been esti-
mated annually in Luxembourg. These estimates take 
account of the total costs to public and private agents 
of the consequences of drug use and trafficking. Public 
spending is analysed in five sectors: prevention, treat-
ment, harm reduction, law enforcement and research. 
In the law enforcement field, as in other fields, the 
analysts face the twofold challenge of accounting 
for drug-related spending, as financed by different 
general government levels, and of developing models 
to extract unlabelled drug-related expenditure from 
broader budgets (Origer, 2002).
Law enforcement was estimated to account for 39% 
of total drug-related public expenditure in 1999; pre-
vention, treatment and harm reduction expenditure 
amounted to 59%, whereas research and other stood 
at 2%. Overall, drug-related public expenditure rep-
resented 0.013% of GDP.
Russia
For Russia, public expenditures on law enforcement 
agencies and on the judicial system were estimated as 
part of a social study (Potapchik and Popovich, 2014). 
The comprehensive model encompassed private and 
indirect costs (the cost for the individual and the 
costs due to loss of productivity) and public spend-
ing, including direct spending on supply reduction 
services. These were disaggregated into spending 
on law enforcement and on criminal justice, which 
included factors such as law enforcement agencies 
and the federal drug control service. 
Public expenditure on supply reduction services was 
estimated using a top-down approach and various 
sources of information: police data on persons caught 
with drugs for personal use; data on the number of 
sentences for drug trafficking; and data on crimes 
related to drug trafficking. As there was no pub-
lished information on the fraction attributable to 
drug-related crime in Russia, the fraction estimated 
in a study by the US Office of National Drug Control 
(22%) was employed with a view to estimating the 
law enforcement and judicial system expenditures. 
Portugal
There are few examples of attempts to estimate 
the impact of changes in the legal system on drug-
related public expenditure and drug-related bud-
gets. Gonçalves et al. (2015) are an exception as they 
conducted a comprehensive social cost analysis of 
the situation before and after decriminalisation in 
Portugal. The authors found a significant reduction in 
the non-health related costs of drug policy between 
2000 and 2004, in particular in the legal system (direct) 
costs. Although these observations highlight signifi-
cant changes, prudence is still called for in concluding 
causal relationships with the new Portuguese National 
Strategy for the Fight against Drugs (NSFAD).
Other national studies
There are other examples of public expenditure studies 
additional to those mentioned above. For instance, 
Mostardt et al. (2010) estimated public expenditure 
in 2006 for Germany using data from Eurostat and 
the COFOG system, concluding that supply reduction 
represented close to 65% of the total drug-related 
public spending; Rigter (2006) estimated that 75% of 
public expenditure was spent on law enforcement in 
the Netherlands; Ramstedt (2006) presented public 
expenditure estimates for Sweden, whereas public 
spending on supply reduction represented between 
70 to 76% of the total; and Lievens et al. (2016) pub-
lished a social cost study, including estimates of public 
expenditure to deal with legal and illegal drugs in 
Belgium. There are also US (ONDCP, 1989-2015) and 
Australian (Moore, 2008) estimates. Despite substantial 
differences, the studies may all be viewed as necessary 
first steps in national drug policy evaluations. 
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International databases 
used to model drug-related 
public expenditure
T he only available international compilation of updated estimates of drug-related public expenditure on supply reduction is published 
by the EMCDDA for the EU member states3, report-
ing the available national estimates of total drug-re-
lated spending and spending separated into sup-
ply and demand reduction initiatives. The scope for 
cross-country comparisons is nonetheless limited 
because the estimates often do not use comparable 
definitions, data sets or methodologies.
Another database of particular relevance is Eurostat. 
This is partly because it is based on a consistent cat-
egorisation system and on internationally agreed 
definitions, which are required features for interna-
tional comparison. The Classification of the Functions 
of Government (COFOG) is a detailed classification 
system for the functions or socioeconomic objectives 
that general government units aim to achieve through 
a range of outlays. Eurostat has published annual data 
according to the COFOG classification for European 
countries since the early 1990s. This data source has 
proved to be relevant and amenable to a wide variety 
of analytic applications. However, the data set does 
not comprise data concerning specific spending on 
drug-related public initiatives. In order to disentangle 
drug-related expenditure from the broad classes of 
public spending, modelling approaches are adopted 
according to the sector of intervention. 
3. See http://www.emcdda.europa.eu/topics/
drug-related-public-expenditure.
Appendix 1 provides a list of relevant data sources. 
In addition to the two data sources already men-
tioned, there is information on international reporting 
concerning supply reduction factors such as: drug 
related crime (EMCDDA and the European Institute 
for Crime Prevention and Control); prison activity 
and costs (the Council of Europe);crime and criminal 
justice systems (Eurostat and the European Institute 
for Crime Prevention and Control). Appendix 3 makes 
an extensive description of data published by inter-
national institutions. 
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Conclusions
► Every European country allocates significant
public resources to the drug policy field. Public 
expenditure studies can reveal how much public 
authorities are spending on drug policy and for 
what purposes such expenditure is incurred.
► Public expenditure estimates can be used as a 
tool for assessing whether policy intentions are 
actually reflected in action, and they constitute 
a necessary tool for implementing thorough
policy evaluations. Public expenditure studies
should mirror all relevant activities and policy
approaches and may be particularly appropriate 
in times of austerity.
► Estimates exist for 16 EU countries, out of the
30 potential reporting countries (EMCDDA,
2014b). Estimates suggested that drug-related 
expenditure ranged from 0.01 % to 0.5 % of GDP. 
12 out of the 16 reporting countries allocate the 
largest share of drug-related public expenditure 
for supply reduction.
► Data availability is one of the main limitations in 
this field. The use of international databases is
recommended, whenever possible. These data
sets employ broadly accepted concepts and
definitions providing better comparable data.
Sometimes, however, national data sets can con-
tain more detailed or reliable information.
► The total budget for supply reduction services 
is the sum of labelled and unlabelled expendi-
tures. Labelled expenditures are clearly iden-
tified in public budgets, whereas a modelling
procedure is required for estimating unlabelled 
ones. The modelling is based on either a top-
down or a bottom-up approach. Using both
approaches as complementary is advantageous 
but expensive. A list of advantages and lim-
itations for both alternatives is provided, in
addition to empirical expenditure studies for
supply reduction activities in some European
countries.
► While recognising the limitations imposed by
the data sets currently available, this report
provides examples of current practice and, in so 
doing, suggests areas of future focus for desired 
methodological development. It is hoped that 
the estimation of drug-related public expendi-
ture on supply reduction initiatives and policy 
evaluation will move forward in Europe. For
continued improvements to take place, how-
ever, it is essential that a network of experts is
developed and maintained. Partnerships should 
be extended and maintained with the goal
of developing good practices, standards and
guidelines in this field.
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Recommendations
1. Improving estimation methods with further meth-
odological developments; agreeing on best prac-
tices and; finding reliable standardised data will
enhance the utility of public expenditure estimates, 
as that will permit analysis over time and across
policy areas and countries.
2. Improved data quality and developing relevant
data sources is needed for conducting more precise 
estimations of spending on drug control measures 
and to measure the impact of drug control policies. 
One option is to develop guidelines for data col-
lection and economic modelling of evaluations.
3. It is essential to classify public expenditure based on 
the purpose for which the expenditure is intended. 
It is therefore useful to use a consistent categorisa-
tion system, such as the international Classification 
of the Functions of Government (COFOG).
4. Cross-country comparisons are important, but
they are only possible with a common methodol-
ogy of public expenditure estimates. International 
data sets and modelling techniques need to be
expanded and improved in order to increase the
capacity to carry evidence based on drug policy
evaluations in the drug field.
5. A methodology using a set of repartition keys
according to COFOG categories can be a starting
point in order to estimate unlabelled drug-related 
expenditures. General agreement among all par-
ticipating countries on definitions and methods
will help to improve the comparability of results
between countries.
6. Public expenditure studies involve analytical work, 
which requires adequate human and technical
capacities in all relevant stakeholder fields. This is
important for obtaining the data quality needed
for aggregation and comparison. To achieve this,
a network of experts could be established and a
working group of experts developed.
7. Developing methods to estimate public expendi-
ture on supply reduction requires effective work-
ing partnerships between drug policymakers and 
specialists in the police, law courts and prisons.
Collaboration with public accountancy experts and 
those in charge of economic modelling is required 
to guarantee meaningful estimates.
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Glossary 
Attributable fractions also known as repartition 
keys are coefficients estimated to help those who 
estimate drug-related expenditure with the purpose 
of reflecting the proportion of expenditure allocated 
to finance drug-related initiatives. Therefore, attrib-
utable fractions are designed to accurately isolate 
drug-spending, when drug-related expenditure is 
embedded into a broader budgetary structure. There 
is no general methodology to determine repartition 
keys. It depends on the case (on the basis of the activ-
ity information and data available) (Vander Laenen 
et al, 2011). 
Cost analysis provides monetary estimates of the 
costs of a particular intervention or set of interven-
tions, and also information on the amount of resources 
(e.g. labour, facility, supplies) used in their provision. 
The latter information is often used to identify critical 
cost components of the intervention and to assess 
whether the costs are affected by changes in key 
assumptions (Bray and Zarkin, 2006). In addition 
to being the first step in a cost-effectiveness and 
cost-benefit analysis, cost studies can also be used 
to compare the relative costs of one intervention to 
another or to monetise savings from implementing 
a particular action (Chalk et al., 2013).
Cost-effectiveness analysis involves estimating 
the ratio of the difference in costs between two 
alternatives (net costs) divided by the difference in 
the outcomes (net effectiveness) (Gold et al., 1996). 
Traditionally, this measure has been used in health 
economics. However, this evaluation tool can be used 
in any framework of policy intervention, given that the 
outcome measures are those relevant for each type 
of public policy analysed. It is, essentially, the incre-
mental price of obtaining a unit outcome effect (e.g. 
a 10% reduction in the number of drug-law offences 
in the past month) from a given police intervention 
(e.g. introducing drug squads in problem neighbour-
hoods) when compared to an alternative (e.g. regular 
policing). Intervention costs are estimated in monetary 
units, such as the euro. The effect of the intervention 
can be any policy-relevant outcome that is collected 
for all interventions under consideration. 
Cost-benefit analysis converts all types of outcomes 
to a monetary equivalent, in contrast to cost-effective-
ness analysis (Chalk et al., 2013 and Drummond et al., 
1997). As a result, the euro value of the intervention’s 
benefits can be directly compared with the euro value 
of the intervention’s costs. Two common methods 
for comparing benefits and costs include calculating 
net benefits (costs are subtracted from benefits) and 
benefit-cost ratios (benefits are expressed as a percent-
age of programme costs). A related type of analysis is 
the cost-offset analysis in which future costs or cost-
savings are examined. Since cost-benefit analyses 
combine multiple outcomes into a single measure 
and allow direct comparison of costs to benefits, they 
often provide clearer guidance than cost-effectiveness 
analyses on which treatment programmes should be 
adopted – namely those programmes whose ben-
efits exceed their costs. Cost-effectiveness analyses 
can provide a ranking of competing alternatives but 
not information on the extrinsic value of any single 
intervention independent of the alternatives (Bray 
and Zarkin, 2006).
General government comprises the central govern-
ment, state government (in some countries it applies 
to the federal level of government), local and social 
security funds (Eurostat, 2011). 
Government expenditure is defined as a particular 
set of transactions, comprising the expending under-
taken by general government sector units (Eurostat, 
2011). 
Economic evaluation is a comparative analysis of 
alternative actions in terms of both their costs and 
consequences (Drummond et al., 1997).
Labelled drug-related expenditure is the ex-ante 
planned public expenditure made by general gov-
ernment in the budget that reflects the public and 
voluntary commitment of a country in the field of 
drugs. In addition, it is any expenditure identified 
as drug-related in public accountancy documents 
(EMCDDA, 2008).
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Public expenditure is the value of goods and services 
purchased by the general government of a state in 
order to perform each of its functions. The functions 
of governments are, among others, the provision of 
health care, justice, public order, education and social 
protection. Public expenditure studies are important 
because they provide information about the size and 
the composition of the costs of public programmes 
and interventions (Eurostat, 2011). 
Social costs of illegal drugs comprise all costs carried 
by the different sectors of society as a consequence 
of the illicit drug phenomenon. Public expenditure 
is only one of the cost elements here. Social cost is 
the sum of public expenditure, private expenditure 
and external costs. Private expenditure constitutes, 
for instance, the money spent by private citizens to 
purchase illicit drugs. External costs comprise the 
costs caused by the consequences of drug use, which 
can affect anyone in society, including those who 
do not necessarily use drugs or are involved in drug 
demand, supply or drug policy. For instance, external 
costs are the expenditure on drug-related nuisance, 
expenditure on tackling offences committed under the 
influence of drugs, losses of productivity or absentee-
ism associated with either drug trafficking or dealing 
activities, among others (Single et al., 2003).
Total drug-related public expenditure is the sum of 
the labelled and unlabelled drug-related expenditure 
(EMCDDA, 2008). 
Unlabelled drug-related expenditure is the non-
planned or non-publicly announced ex-post public 
expenditure incurred by the general government in 
tackling drugs that is not identified as drug-related 
in the budget (EMCDDA, 2008).
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Appendix 1 – Available databases 
and potential indicators for drug-
related public expenditures 
Examples of international databases, which can be used for estimating drug-related 
public expenditures
Level of 
estimation Examples of databases Estimation data
International EMCDDA Statistical 
bulletin
and 
Public expenditure 
database
 – The EMCDDA statistical bulletin covers a broad range of 
areas including the most recent estimates of drug-related 
crime in the form of drug seizures, types of offence, price, 
purity and use in prison, and country responses to the 
drug situation in Europe. http://www.emcdda.europa.eu/
data/stats2015
 – The EMCDDA also publishes the most recent national data 
on drug-related public expenditures available in Europe. 
 – http://www.emcdda.europa.eu/topics/
drug-related-public-expenditure
WHO Database  – Global Information System on Resources for the 
Prevention and Treatment of Substance Use Disorders 
(includes information about: prevalence and burden of 
Disease, monitoring and surveillance; policy; treatment 
system and services; pharmacological treatment; preven-
tion programmes for substance use and related harm; and 
human resources and civil society involvement).
Eurostat Public expenditure according to the Classification of the 
Functions of Government (COFOG)
COFOG published data according to two levels of classification 
(United Nations, 2008). The first classifies expenditure into 10 
general functions, one of which is “Public order and safety”. The 
second classifies expenditure into 69 groups, in which there 
are three indicators of interest: police service, law courts and 
prisons. The definitions below are provided by the UNODC.
From the Public order and safety section:
Police services
 – Administration of police affairs and services, including alien 
registration, issuing work and travel documents to immi-
grants, maintenance of arrest records and statistics related to 
police work, road traffic regulation and control, prevention 
of smuggling and control of offshore and ocean fishing.
 – Operation of regular and auxiliary police forces, of port, 
border and coast guards, and of other special police forces 
maintained by public authorities; operation of police labora-
tories; operation or support of police training programmes.
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Level of 
estimation Examples of databases Estimation data
Law Courts
 – Administration, operation or support of civil and criminal 
law courts and the judicial system, including enforcement 
of fines and legal settlements imposed by the courts and 
operation of parole and probation systems.
 – Legal representation and advice on behalf of the govern-
ment or on behalf of others provided by government, in 
cash or in services.
Prisons
 – Administration, operation or support of prisons and other 
places for the detention or rehabilitation of criminals such 
as prison farms, workhouses, reformatories, asylums for the 
criminally insane, etc.
UN-CTS (Crime and 
Criminal Justice 
Statistics)
Data produced by UNODC have multiple sources. Mem-
ber States regularly submit to UNODC statistics on drugs 
(through the Annual Report Questionnaire) and crime and 
criminal justice (through the annual Surveys on Crime Trends 
and Operations of Criminal Justice Systems). Other data are 
collected through national surveys implemented by UNODC 
in co-operation with national governments or are compiled 
from scientific literature. UNODC attempts to maximise the 
comparability of the data and estimate regional and global 
statistics.
SPACE SPACE unites two related projects: SPACE I provides data 
on penal institutions and the population held in custody, 
as well as on certain conditions of detention, while SPACE 
II collects information on persons serving non-custodial 
sanctions and alternative measures.
Data are collected every two years by means of two question-
naires sent to the equivalents of the ministries of justice, the 
penitentiary administrations and the probation authorities of 
each country in Europe. The collection and validation of these 
data then takes place at the University of Lausanne, where 
analyses and interpretations for both projects are formulated 
through a common methodology. This methodology aims 
to allow comparisons among states at European level, by 
proposing SPACE categories instead of each country’s own 
national categories, while still including questions regarding 
the particularities of their specific sanctions and measures. The 
SPACE project produces two annual reports: SPACE I – Prison 
Populations and SPACE II – Persons Serving Non-Custodial 
Sanctions and Measures, presenting the data collected and 
the key points of the results.
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Level of 
estimation Examples of databases Estimation data
European Sourcebook 
on Crime and Criminal 
Justice Statistics
The Sourcebook contains data from 41 European countries 
regarding their criminal justice systems. The book is structured 
into six main chapters covering different stages of the judicial 
system: Police Statistics, Prosecution Statistics, Conviction 
Statistics, Prison Statistics, Probation Statistics and, for the 2014 
edition, a final chapter on National Victimization Surveys. The 
data provided are systematically accompanied by texts and 
notes relating to the specificity of each country and which 
discuss the different challenges attributed to the comparison 
of the data.
Social Expenditure 
Database
The OECD Social Expenditure Database (SOCX) provides a 
unique tool for monitoring trends in aggregate social expendi-
ture and analysing changes in its composition. The main social 
policy areas are as follows: old age, survivors, incapacity-related 
benefits, health, family, active labour market programmes, 
unemployment, housing, and other social policy areas.
ESPAD Drug abuse prevalence among teenagers in European 
countries.
National Database of national 
statistics
Expenditures of different groups, in which can be found some 
indicators of interest: police service, law courts, prisons, medi-
cal and social services. 
Annual report from 
Social Services 
Department
Data on Social Services Department expenditures at regional 
level and the number of drug users receiving social benefits 
in connection with drug use.
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Appendix 2 – The international 
Classification of the Functions 
of Government (COFOG)
T he COFOG classification has three structural levels. At the first level, government expenditure is broken down into 10 functions. These are then 
divided into 69 groups (second level of COFOG), which 
are themselves divided into classes at the third level – 
the most detailed classification level. COFOG permits 
an examination over time of trends in government 
outlays on particular functions (Eurostat, 2011).
The detailed three-level structure of COFOG includes 
financial flows of public finance, which are going from 
state and local (regional and municipal) budgets to 
non-profit organisations (NPOs) with drug-policy 
programmes. COFOG is a functional classification 
system used by the System of National Accounts 
1993. COFOG is a useful international classification 
system for spatial comparison (between countries) 
and also for time comparison (over time). In principle, 
its units of classification are individual transactions. 
This means that each outlay (purchase or transfer) 
should be assigned a COFOG code according to the 
function that the transaction serves. This principle is 
valid for both capital transfers (investment) and current 
(non-investment) transfers. Eurostat has published 
annual data according to the COFOG definitions for 
the European Union countries since the early 2000s.
The extensive structure of COFOG contrasts with the 
four-category division introduced by Reuter (2006), 
based on the likely effects of services provided by 
drug policy programmes (namely prevention, treat-
ment, enforcement and harm reduction). Reuter’s 
programme division is the classification of the recip-
ients (NPOs) with drug-policy programmes. 
An example of an overview of public expenditure 
groups, broken down according to the main public 
functions pursuant to the international classification 
of the functions of the government at the third level, 
is shown in the table below.
A pragmatic approach towards drug-related research 
and public expenditure estimates would suggest 
adopting a classification such as COFOG, as proposed 
by Eurostat. The COFOG classification system guar-
antees annually available data for most European 
countries, according to harmonised definitions and 
standard data collection procedures. 
Public expenditures according to the classification of public functions
Public functions Public functions at the third level of classification
01 General public services 014 Basic research
03 Public order and safety 031 Police services
033 Law courts
034 Prisons
07 Health 071 Medical products, appliances and equipment
072 Outpatient services
073 Hospital services
074 Public health services
075 R&D health
09 Education 091 Pre-primary and primary education
092 Secondary education
094 Tertiary education
095 Education non-definable by level
096 Subsidiary services to education
10 Social protection 105 Unemployment
106 Housing 
107 Social exclusion 
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Appendix 3 – Summary tables: 
data from international databases
Table 1 - Public expenditure
Data and 
Statistics
Dataset Type of 
information
DATABASE YEARS Number of 
observations(*) 
Public 
expenditure
Expenditure 
of the 
general 
government
Law Courts Eurostat, 
European 
Union 
(EU)
1995-2015
Europe (31) = 473/651
Police Services Europe (31) = 473/651
Prisons Europe (31) = 473/651
Drug-
related 
public 
expenditure
Public 
expenditure 
on supply 
reduction
Total drug-
related public 
expenditure
Country Drug 
Profiles,
EMCDDA, (EU)
Last year 
available EU (30) =20/30
Percentage 
spent on supply 
reduction
Percentage spent 
on demand 
reduction
(*) The number of observations reports the number of data records, taking into account the territory; countries and years available. 
The ratio compares the number of effectively reported observations with the total number of records, if no data were missing. 
Example: Europe (44) = 28/368: in Table 4, the conviction statistics of the European Sourcebook of crime and criminal justice sta-
tistics reports 28 data records, for the community sanctions imposed to drug offences in 2010, compared to the 368 data records 
that would exist if no data were missing, in the region Europe (which accounts with 44 countries). 
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Table 2 – Drug law offences
Data and 
Statistics Dataset Type of information DATABASE Years
Number of 
observations(*)
Drug law 
offences
Drug Law 
Offences
Number 
of 
offences
Offences
EMCCDA
(EU)
1995-2014
EU (30) = 364/600
Offender EU (30) = 262/600
Offences 
by Types
Use
2004-2013
EU (30) = 230/300
Supply EU (30) = 238/300
Offences 
by drug
Cannabis
Total 2004-2013 EU (30) = 203/300
Use
2005-2013
EU (30) = 163/270
Supply EU (30) = 160/270
Heroin
Total 2004-2013 EU (30) = 186/300
Use
2005-2013
EU (30) = 159/270
Supply EU (30) = 160/270
Cocaine
Total 2004-2013 EU (30) = 185/300
Use
2005-2013
EU (30) = 159/270
Supply EU (30) = 176/270
Crack
Total
2005-2013
EU (30) = 50/270
Use EU (30) = 47/270
Supply EU (30) = 37/270
Amphetamine
Total
2005-2013
EU (30) = 163/270
Use EU (30) = 74/270
Supply EU (30) = 87/270
Methamphetamine
Total
2005-2013
EU (30) = 98/270
Use EU (30) = 74/270
Supply EU (30) = 87/270
Ecstasy 
Total
2005-2013
EU (30) = 162/270
Use EU (30) = 144/270
Supply EU (30) = 153/270
LSD
Total
2005-2013
EU (30) = 127/270
Use EU (30) = 108/270
Supply EU (30) = 95/270
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Table 3 – Prison population
Data and 
Statistics Dataset Type of information DATABASE YEARS
Number of 
observations(*)
Prison 
population
Persons held in 
institutions for drug 
users offenders 
outside penal 
institutions
Availability of 
institutions for drug 
users offenders, 
outside penal 
institutions
Space I, 
Council of 
Europe (CoE)
2014 CoE (47) =28/53
Situation of prison 
population
Population on 
1st January 
2009 & 
2014
2009: CoE (47) = 343/424
2014: COE (47) = 255/265
Total number of 
prisoners (including 
pre-trial detainees)
Total number of 
detainees held in 
remand institutions/
sections (pre-trials)
Total number of 
prisoners held in 
institutions serving 
a sentence
Total capacity of 
penal institutions
Surface area per 
prisoner (m^2) 
Evolution of prison 
population
Total number 
of prisoners 2000-2014
CoE (47) = 707/795
Prison population CoE (47) = 683/795
Legal status of 
prison population
Untried detainees 
(no court decision)”
2009 &
2014
2009: CoE (47) = 274/424
2014: CoE (47) = 315/477
Detainees found 
guilty but no 
sentence yet
Sentenced prisoners 
(appealed or 
can do so)
Detainees with no 
final sentence, but 
serving a prison 
sentence in advance
Sentenced prisoners 
(final sentence), 
of which:
 – fine defaulters
 – in revocation, 
suspension or 
annulment of the 
conditional release 
or probation
Other cases
Total number of 
prisoners (including 
pre-trial detainees)
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Data and 
Statistics Dataset Type of information DATABASE YEARS
Number of 
observations(*)
Main offence of 
sentenced prisoners 
(Final Sentence) 
Drug offences 2009 & 2014 CoE (47) = 88/106
Lengths of 
sentences imposed 
(final sentenced 
prisoners)
Length of the 
sentences by month, 
years or lifetime
2009 CoE (47) = 405/583
2014 CoE (47) = 557/689
Prison population 
(including pre-trial 
detainees): stock
Prison population
Stock – Total
European 
Sourcebook 
of crime 
and criminal 
justice 
statistics,
Université de 
Lausanne
2003-2011
Europe (44) = 387/414
Prison population
Pre-trial detainees
Europe (44) = 356/414
Convicted prison 
population by 
type of offence
Total criminal offences 2006 & 2010 Europe (44) = 88/92
Drug offences 
(of which %) 2010 Europe (44) = 38/46
Convicted prison 
population in 2010 
Drug offences: Total
2006 & 
2010 Europe (44) = 46/92
Sentenced persons 
held in prisons
Drug Offences
UNODC 2010-2012
Europe (26) = 49/81
Drug Trafficking Europe (26) =36/81
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Table 4 – Cases registered by the police, prosecutors and law courts
Data and 
Statistics Dataset Type of information DATABASE YEARS
Number of 
observations(*)
Police 
statistics
Crime 
Recorded by 
the Police
Total
Eurostat
1993-2007 Europe (36) = 536/585
Unlawful acts involving 
controlled drugs or precursors
1993-2007 Europe (36) = 486/585
2008-2014 Europe (39) = 275/287
Drug-Related 
Crimes at 
the national 
level, number 
of police-
recorded 
offences
Total
UNODC 2003-2008
Europe (40) = 215/258
Drug Possession Europe (21) = 101/138
Drug Trafficking Europe (37) = 175/240
Police 
Statistics- 
Offences/
Offenders
Offences
Criminal Offences
European 
Sourcebook 
of crime 
and criminal 
justice 
statistics
2003-2011
Europe (42) = 347/387
Drug Offences Europe (42) = 333/387
Drug Trafficking Europe (41) = 269/387
Offenders
Criminal Offenders Europe (42) = 263/396
Drug Offenders Europe (42) = 245/396
Drug Trafficking Europe (42) = 190/396
Conviction 
statistics
Criminal cases 
handled by the 
prosecuting 
authorities 
Output cases: Total
2003-2011
Europe (42) = 218/396
Percentage brought before 
a court of the total output of 
criminal cases handled by the 
prosecuting authorities
Europe (42) = 198/396
Output 
cases by 
offence 
group
Drug Offences
2010
Europe (42) = 33/88
Drug Trafficking Europe (42) = 25/88
Convictions 
Statistics- 
Persons 
convicted
Criminal offences
2003-2011
Europe (42) = 293/369
Drug offences Europe (42) = 272/369
Drug trafficking Europe (42) = 193/369
Total persons 
receiving 
sanctions/
measures
Criminal offences
2006 Europe (41) = 203/473
2010 Europe (41) = 176/602
Drug offences
2006 Europe (41) = 175/473
2010 Europe (41) = 158/602
Drug trafficking
2006 Europe (41) = 113/473
2010 Europe (41) = 104/602
Community 
sanctions and 
measures 
imposed
Criminal offences
2010
Europe (44) = 52/368
Drug offences Europe (44) = 28/368
► Page 36
Acronyms
Council of Europe (47) = CoE(47): Albania, Andorra, 
Armenia, Austria, Azerbaijan, Belgium, Bosnia-
Herzegovina, Bulgaria, Croatia, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Georgia, 
Germany, Greece, Hungary, Iceland, Ireland, Italy, 
Latvia, Liechtenstein, Lithuania, Luxembourg, 
Malta, Republic of Moldova, Monaco, Montenegro, 
Netherlands, Norway, Poland, Portugal, Romania, 
Russian Federation, San Marino, Serbia, Slovak 
Republic, Slovenia, Spain, Sweden, Switzerland, “The 
former Yugoslav Republic of Macedonia”, Turkey, 
Ukraine, United Kingdom 
European Union (30)= EU(30): Austria, Belgium, 
Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, 
Estonia, Finland, France, Germany, Greece, Hungary, 
Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, 
Netherlands, Norway, Poland, Portugal, Romania, 
Slovakia, Slovenia, Spain, Sweden, Turkey, United 
Kingdom
Europe (21): Belarus, Bulgaria, Czech Republic, 
Hungary, Poland, Romania, Finland, Iceland, Lithuania, 
Norway, Sweden, United Kingdom, Albania, Croatia, 
Malta, Slovenia, Belgium, France, Liechtenstein, 
Luxembourg, Switzerland
Europe (26): Bulgaria, Czech Republic, Poland, Romania, 
Russian, Denmark, Estonia, Finland, Ireland, Latvia, 
Lithuania, Norway, Sweden, United Kingdom, Andorra, 
Greece, Italy, Malta, Portugal, Serbia, Slovenia, Austria, 
Liechtenstein, Monaco, Netherlands, Switzerland
Europe (31): Austria, Belgium, Bulgaria, Croatia, 
Cyprus, Czech Republic, Denmark, Estonia, Finland, 
France, Germany, Greece, Hungary, Ireland, Italy, Latvia, 
Lithuania, Luxembourg, Malta, Netherlands, Norway, 
Poland, Portugal, Romania, Slovakia, Slovenia, Spain, 
Sweden, Turkey, United Kingdom
Europe (36): Europe (31) + Liechtenstein, Montenegro, 
TRF-Macedonia, Serbia, Turkey
Europe (37): Europe (21) + Republic of Moldova, 
Russian Federation, Slovakia, Ukraine, Denmark, 
Estonia, Ireland, Bosnia-Herzegovina, Italy, 
Montenegro, Portugal, Serbia, Spain, TRF- Macedonia, 
Germany, Monaco
Europa (39): Europe (36) + Albania, Bosnia-
Herzegovina, Kosovo
Europa (40): Belarus, Bulgaria, Czech Republic, 
Hungary, Poland, Moldova, Romania, Slovakia, 
Ukraine, Denmark, Estonia, Finland, Iceland, Ireland, 
Latvia, Lithuania, Norway, Sweden, United Kingdom, 
Albania, Bosnia-Herzegovina, Croatia, Greece, Italy, 
Malta, Montenegro, Portugal, Serbia, Slovenia, Spain, 
TRF- Macedonia, Austria, Belgium, France, Germany, 
Liechtenstein, Luxembourg, Monaco, Netherlands, 
Switzerland
Europa (41): Europa (42), except Luxembourg
Europe (42): Europa (31) + Albania, Armenia, Bosnia-
Herzegovina, Georgia, Kosovo, Moldova, Russia, Serbia, 
TRF- Macedonia, Turkey, Ukraine
Europe (44): Europe (42) + Azerbaijan, Montenegro
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The Council of Europe is the continent’s 
leading human rights organisation. 
It comprises 47 member states, 28 of which 
are members of the European Union. 
All Council of Europe member states have signed up to 
the European Convention on Human Rights, a treaty designed 
to protect human rights, democracy and the rule of law.
The European Court of Human Rights oversees 
the implementation of the Convention in the member states.
Evaluating drug policy is an integral part of a cost-efficient 
approach to tackle illicit drugs. This report takes a first 
step towards a systematic analysis, by examining a set of 
representative attempts to estimate public expenditure 
on supply reduction interventions. It proposes a common 
set of definitions, aiming to establish a common basis for 
understanding this topic and facilitating comparability in three 
main dimensions: time, policy and countries. Although it is 
mainly confined to supply reduction expenditures, in order to 
set the context, it describes the proportion that total drug-
related expenditure represents of national public spending and; 
presents the balance between demand and supply reduction 
spending for a number of European countries. Finally, with the 
aim of facilitating and promoting future empirical expenditure 
studies and of setting the ground for the development of 
good practices, relevant data sources and methodologies 
applied are listed and discussed and examples of sectorial 
models of public spending are selectively provided.
